• Je něco špatně v tomto záznamu ?

HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control

M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,

. 2018 ; 149 (-) : 214-224. [pub] 20171104

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, validační studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033577

An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033577
003      
CZ-PrNML
005      
20181009110307.0
007      
ta
008      
181008s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jpba.2017.11.018 $2 doi
035    __
$a (PubMed)29126083
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Douša, Michal $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic. Electronic address: michal.dousa@seznam.cz.
245    10
$a HPLC/UV/MS method application for the separation of obeticholic acid and its related compounds in development process and quality control / $c M. Douša, M. Slavíková, T. Kubelka, J. Černý, P. Gibala, J. Zezula,
520    9_
$a An HPLC method with UV and electrospray ionization - mass spectrometry (ESI-MS) detection was developed for the separation and determination of obeticholic acid (OBE) and its related compounds in development process and quality control. OBE and its related compounds were classified into three major group based on the mass spectra profiles: (A) those containing a hydroxyl group at position 3 and 7, (B) those containing a hydroxyl group and/or carbonyl group at position 3, hydrogen, ethyl or ethylidene group at position 6 and a hydroxyl group and/or carbonyl group at position 7, and (C) those containing carbonyl groups at position 3 and 7. ESI-MS ionization of OBE and its related compounds often produced intense adduct ions [M+H+98]+ and/or [M+H+196]+ that were identified as the adduct ions of phosphoric acid ([M+H+H3PO4]+ and [M+H+2H3PO4]+) originating from the mobile phase. The separation on HPLC system was accomplished using stationary phase based on XSelect CSH C18 (3.0×150mm×2.5μm) and a linear gradient elution using acetonitrile and 0.05% of o-phosphoric acid. The condition of chromatographic system was set as follows: flow rate 0.7mL/min, temperature 45°C and UV detection at 192nm. The separation of the 19 compounds was finished in less than 18min (including equilibration time). The HPLC/UV method was partially validated according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines in terms of repeatability, selectivity, linearity and limit of quantification and detection.
650    _2
$a chemická frakcionace $x přístrojové vybavení $x metody $7 D005591
650    _2
$a farmaceutická chemie $x metody $7 D002626
650    _2
$a kyselina chenodeoxycholová $x analogy a deriváty $x analýza $x chemie $7 D002635
650    _2
$a vysokoúčinná kapalinová chromatografie $x přístrojové vybavení $x metody $7 D002851
650    _2
$a příprava léků $x přístrojové vybavení $x metody $7 D004339
650    _2
$a kontaminace léku $x prevence a kontrola $7 D004340
650    _2
$a limita detekce $7 D057230
650    12
$a řízení kvality $7 D011786
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a senzitivita a specificita $7 D012680
650    _2
$a hmotnostní spektrometrie s elektrosprejovou ionizací $x přístrojové vybavení $x metody $7 D021241
650    _2
$a spektrofotometrie ultrafialová $x přístrojové vybavení $x metody $7 D013056
655    _2
$a časopisecké články $7 D016428
655    _2
$a validační studie $7 D023361
700    1_
$a Slavíková, Markéta $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Kubelka, Tomáš $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Černý, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Gibala, Petr $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
700    1_
$a Zezula, Josef $u Zentiva, k.s. Praha, A Sanofi Company, U Kabelovny 130, 102 37 Praha 10, Czech Republic.
773    0_
$w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 149, č. - (2018), s. 214-224
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29126083 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181009110755 $b ABA008
999    __
$a ok $b bmc $g 1340211 $s 1030571
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 149 $c - $d 214-224 $e 20171104 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...